PRODUCT INFORMATION



Mildronate (hydrate)

Item No. 15997

CAS Registry No.: 86426-17-7

Formal Name: 2-(2-carboxyethyl)-1,1,1-trimethyl-

hydrazinium, inner salt, dihydrate

Synonyms: Meldonium, MET-88, Quaterine, THP


MF: $C_6H_{14}N_2O_2 \bullet 2H_2O$

182.2 FW: **Purity:** ≥98%

Supplied as: A crystalline solid

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Mildronate (hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the mildronate (hydrate) in the solvent of choice, which should be purged with an inert gas. Mildronate (hydrate) is soluble in the organic solvent ethanol at a concentration of approximately 25 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of mildronate (hydrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of mildronate (hydrate) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Mildronate is a structural analog of γ-butyrobetaine (γBB), an intermediate in the biosynthesis of carnitine. It blocks carnitine synthesis by inhibiting γBB hydroxylase (IC₅₀ = 62 μM) and, less potently, carnitine acetyltransferase ($K_i = 1.6 \text{ mM}$). 1-3 Through these actions, mildronate reduces the levels of free carnitine and long chain acyl carnitine. 4-5 This leads to suppressed fatty acid metabolism and mitochondrial uncoupling during oxidative conditions, resulting in cardioprotective and neuroprotective effects.⁴⁻⁶ Mildronate also improves cognition and reduces amyloid-β pathology in a mouse model of Alzheimer's disease.⁷

References

- 1. Tars, K., Leitans, J., Kazaks, A., et al. J. Med. Chem. 57(6), 2213-2236 (2014).
- 2. Leung, I.K., Krojer, T.J., Kochan, G.T., et al. Chem. Biol. 17(12), 1316-1324 (2010).
- 3. Jaudzems, K., Kuka, J., Gutsaits, A., et al. J. Enzyme Inhib. Med. Chem. 24(6), 1269-1275 (2009).
- 4. Simkhovich, B.Z., Shutenko, Z.V., Meirena, D.V., et al. Biochem. Pharmacol. 37(2), 195-202 (1988).
- 5. Makrecka, M., Svalbe, B., Volska, K., et al. Eur. J. Pharmacol. 723, 55-61 (2014).
- 6. Klusa, V., Beitnere, U., Pupure, J., et al. Medicina (Kaunas) 49(7), 301-309 (2013).
- 7. Beitnere, U., van Groen, T., Kumar, A., et al. J. Neurosci. Res. 92(3), 338-346 (2014).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 11/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM